NeuroPace Inc (NPCE) stock
Close on Nov 11, 2026Market cap $429.74MP/E –Yield 0.00%
NeuroPace Inc grew revenue 16.9% to $98.84M over the twelve months to Jun 30, 2026. Free cash flow was -$11.61M. At the latest close the market valued the company at $429.74M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $429.74M
- P/E ratio
- –
- Price to sales
- 4.35
- Price to book
- 36.16
- Dividend yield
- 0.00%
- Free cash flow yield
- -2.70%
Fundamentals
- Revenue
- $98.84M
- Net income
- -$19.11M
- EPS, diluted
- -$0.57
- Free cash flow
- -$11.61M
- Book value per share
- $0.35
- Diluted shares
- 34M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $12.69
- Open
- $12.81
- Day's range
- $12.46 – $12.94
- Volume
- 89,281
- Average volume (20 days)
- 123,770
- Index membership
- Russell 2000 (since Sep 2024), Russell 3000 (since Aug 2024)
- Beta (5 years)
- 1.07
- 52-week range
- $12.00 – $19.60
- RSI (14 days)
- 45.3
- Volatility (1 year)
- 50.5%
- Relative volume
- 0.57×
- WACC
- 10.0%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NPCE | S&P 500 | Difference | NPCE per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.2% | -2.4% | +1.2 pts | ||
| 3 months | -16.8% | -1.2% | −15.7 pts | ||
| Year to date | -18.9% | +12.3% | −31.2 pts | ||
| 1 year | -7.2% | +12.4% | −19.6 pts | ||
| 3 years | +59.5% | +78.8% | −19.3 pts | +16.8% | +21.4% |
| 5 years | -10.6% | +75.2% | −85.7 pts | -2.2% | +11.9% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases NeuroPace filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About NeuroPace
Surgical & Medical Instruments & Apparatus
The company develops and commercializes medical devices designed to treat epilepsy by reducing or eliminating seizures. Its primary product is the RNS System, a brain-responsive neuromodulation system that continuously monitors intracranial brain activity, identifies individualized abnormal patterns, and delivers targeted electrical pulses to the seizure origin. In addition to the implantable neurostimulator and lead components, the platform includes clinician and patient management tools such as the Patient Remote Monitor, the Physician Tablet, the Patient Data Management System, and the nSight Platform. Its customer base consists of epileptologists, functional neurosurgeons, and comprehensive epilepsy centers treating adult patients with drug-resistant focal epilepsy.
Company profile, executives and historyNeuroPace stock: common questions
What is NeuroPace's stock price?
NPCE closed at $12.52 on Nov 11, 2026, down 1.34% on the day. Over the past 52 weeks it traded between $12.00 and $19.60.
What is NeuroPace's market cap?
NeuroPace was worth $429.74M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NPCE's P/E ratio?
NeuroPace lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.57), so it has no meaningful P/E ratio.
How much revenue does NeuroPace make?
NeuroPace reported revenue of $98.84M for the twelve months to Jun 30, 2026, up 16.9% from a year earlier.
Does NeuroPace pay a dividend?
No. NeuroPace has not paid a cash dividend over the last twelve months.
When does NeuroPace report earnings next?
NeuroPace's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has NPCE stock performed over the past year?
Including dividends, NPCE returned -7.2% over the past year, against +12.4% for the S&P 500.
How many NPCE shares are sold short?
1M shares were sold short at the latest FINRA report, 3.00% of the float, or 8.5 days of average trading volume.
Who are NeuroPace's competitors?
Companies most similar to NeuroPace by business, industry and size include CVRX, BWAY, STIM, CBLL, LUNG.
See a number that looks wrong?